Novavax is reportedly delaying signing a contract to supply its COVID-19 vaccine to the EU due to production issues.
According to a Reuters report, the company is struggling to source some of the raw materials for the vaccine.
Earlier this year, the EU was planning to a sign a deal for at least 100 million doses of Novavax's vaccine, with an option to buy another 100 million doses. The Reuters report suggests that a EU official involved in the deal said that Novavax was delaying signing a deal for weeks, citing legal issues in meetings.
Earlier this month, Novavax announced positive Phase 3 results from its U.K. trial of a vaccine candidate against COVID-19. The vaccine candidate had a final efficacy of 86.3% against the U.K. variant of COVID-19.
The vaccine candidate had 96.4% efficacy against the original COVID-19.